The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-02 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
I am patriot enough to take pains to bring this useful invention into fashion in England, and I should not fail to write to some of our doctors very particularly about it if I knew any one of them that I thought had virtue enough to destroy such a considerable branch of their revenue for the good of mankind, but that distemper is too beneficial to them not to expose to all their resentment the hardy wight that should undertake to put an end to it. Perhaps if I live to return I may, however, have courage to war with them.
Early in the game, the player is given a research camera; by taking photographs of enemies, the player will cumulatively gain knowledge about the individual foes which translates into attack boosts and other benefits when facing that enemy type in the future. The player collects money by exploring Rapture and from the bodies of defeated foes; this money can be used at vending machines to restock on ammunition, health and EVE, and other items; like security cameras, vending machines can be hacked to reduce the costs of items from it.
Emotion focused therapy/Emotionally focused therapy (EFT), not to be confused with Emotional Freedom Techniques, was initially informed by humanistic–phenomenological and Gestalt theories of therapy. "Emotion Focused Therapy can be defined as the practice of therapy informed by an understanding of the role of emotion in psychotherapeutic change. EFT is founded on a close and careful analysis of the meanings and contributions of emotion to human experience and change in psychotherapy. This focus leads therapist and client toward strategies that promotes the awareness, acceptance, expression, utilization, regulation, and transformation of emotion as well as corrective emotional experience with the therapist. The goals of EFT are strengthening the self, regulating affect, and creating new meaning". Similarly to some Psychodynamic therapy approaches, EFT pulls heavily from attachment theory. Pioneers of EFT are Les Greenberg and Sue Johnson. EFT is often used in therapy with individuals, and may be especially useful for couples therapy. Founded in 1998, Sue Johnson and others lead the International Centre for Excellence in Emotion Focused Therapy (ICEEFT) where clinicians can find EFT training internationally. EFT is also a commonly chosen modality to treat clinically diagnosable trauma.
== Common examples == When food is cooked, some of its proteins become denatured. This is why boiled eggs become hard and cooked meat becomes firm. A classic example of denaturing in proteins comes from egg whites, which are typically largely egg albumins in water. Fresh from the eggs, egg whites are transparent and liquid. Cooking the thermally unstable whites turns them opaque, forming an interconnected solid mass. The same transformation can be effected with a denaturing chemical. Pouring egg whites into a beaker of acetone will also turn egg whites translucent and solid. The skin that forms on curdled milk is another common example of denatured protein. The cold appetizer known as ceviche is prepared by chemically "cooking" raw fish and shellfish in an acidic citrus marinade, without heat.
Sources: en.wikipedia.org
=== 2009, Tucker & Tenorio === In 2009 John K. Tucker and Manuel J. Tenorio proposed a classification system for the cone shells and their allies (which resorb their inner walls during growth) was based upon a cladistical analysis of anatomical characters including the radular tooth, the morphology (i.e., shell characters), as well as an analysis of prior molecular phylogeny studies, all of which were used to construct phylogenetic trees. In their phylogeny, Tucker and Tenorio noted the close relationship of the cone species within the various clades, corresponding to their proposed families and genera; this also corresponded to the results of prior molecular studies by Puillandre et al. and others. This 2009 proposed classification system also outlined the taxonomy for the other clades of Conoidean gastropods (that do not resorb their inner walls), also based upon morphological, anatomical, and molecular studies, and removes the turrid snails (which are a distinct large and diverse group) from the cone snails, and creates a number of new families. Tucker and Tenorio's proposed classification system for the cone shells and their allies (and the other clades of Conoidean gastropods ) is shown in Tucker & Tenorio cone snail taxonomy 2009.
=== Sources === Grant, Michael (1993). The History of Rome. Faber and Faber. ISBN 0-571-11461-X. Lane Fox, Robin (2005). The Classical World. Penguin Books. ISBN 0-14-102141-1. Matyszak, Philip (2004). The Enemies of Rome. New York: Thames and Hudson. ISBN 0-500-25124-X. Musti, Domenico (1990). "La spinta verso il Sud: espansione romana e rapporti "internazionali"". Storia di Roma. Vol. I. Turin: Einaudi. ISBN 978-88-06-11741-2.
On 23 January 2026, Danish prime minister Mette Frederiksen visited Greenland to express support for the people and the island's self-governing government, following comments by US president Donald Trump indicating his willingness to annex the territory. Trump had previously discussed strengthening security in the Arctic region with NATO secretary general Mark Rutte. Both the Danish and Greenlandic governments have affirmed that the island's sovereignty is indisputable, but remain open to discussions on issues such as security and economic development. The crisis eased after Trump withdrew threats of force and new tariffs.
Sources: en.wikipedia.org
Most RTGs use 238Pu, which decays with a half-life of 87.7 years. RTGs using this material therefore diminish in power output by a factor of 1 – (1/2)1/87.7, or 0.787%, per year. One example is the MHW-RTG used by the Voyager probes. In the year 2000, 23 years after production, the radioactive material inside the RTG had decreased in power by 16.6%, i.e. providing 83.4% of its initial output; starting with a capacity of 470 W, after this length of time it would have a capacity of only 392 W. A related loss of power in the Voyager RTGs is the degrading properties of the bi-metallic thermocouples used to convert thermal energy into electrical energy; the RTGs were working at about 67% of their total original capacity instead of the expected 83.4%. By the beginning of 2001, the power generated by the Voyager RTGs had dropped to 315 W for Voyager 1 and to 319 W for Voyager 2. By 2022, these numbers had dropped to around 220 W. NASA has developed a multi-mission radioisotope thermoelectric generator (MMRTG) in which the thermocouples would be made of skutterudite, a cobalt arsenide (CoAs3), which can function with a smaller temperature difference than the current tellurium-based designs. This would mean that an otherwise similar RTG would generate 25% more power at the beginning of a mission and at least 50% more after seventeen years. NASA hopes to use the design on the next New Frontiers mission.
2 HO–CH2CH2–Cl + Ca(OH)2 → 2 (CH2CH2)O + CaCl2 + 2H2O The produced ethylene oxide is purified by distillation. The chlorohydrin process allows to reach 95% conversion of ethylene chlorohydrin. The yield of ethylene oxide is about 80% of the theoretical value; for 1 tonne (0.98 long tons; 1.1 short tons) of ethylene oxide, about 200 kg (440 lb) of ethylene dichloride is produced. But, the major drawbacks of this process are high chlorine consumption and effluent load. This process is now obsolete.
[Adenosyl−O−PO2−O−PO2−O−PO3]4− + ROH → [Adenosyl−O−PO2−O−PO3H]2− + [RO−P−O3]2− This equation can be written in several ways that are nearly equivalent that describe the behaviors of various protonated states of ATP, ADP, and the phosphorylated product. As is clear from the equation, a phosphate group per se is not transferred, but a phosphoryl group (PO3-). Phosphoryl is an electrophile. This process and its inverse, dephosphorylation, are common in biology. Protein phosphorylation often activates (or deactivates) many enzymes.
is the liquid-air surface tension (force/unit length), θ is the contact angle, ρ is the density of liquid (mass/volume), g is the local acceleration due to gravity (length/square of time), and r is the radius of tube. As r is in the denominator, the thinner the space in which the liquid can travel, the further up it goes. Likewise, lighter liquid and lower gravity increase the height of the column. For a water-filled glass tube in air at standard laboratory conditions, γ = 0.0728 N/m at 20 °C, ρ = 1000 kg/m3, and g = 9.81 m/s2. Because water spreads on clean glass, the effective equilibrium contact angle is approximately zero. For these values, the height of the water column is
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.